Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR A763_Y764insFQEA

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR A763_Y764insFQEA	Lung Cancer	EGFR A763_Y764insFQEA	Lung Cancer	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
EGFR A763_Y764insFQEA	Lung Cancer	EGFR A763_Y764insFQEA	Lung Cancer	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR A763_Y764insFQEA	Lung Cancer	EGFR A763_Y764insFQEA	Lung Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR A763_Y764insFQEA	Lung Cancer	EGFR A763_Y764insFQEA	Lung Cancer	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C4 – Case Studies Tyrosine kinase inhibitor Sensitive : C4	Tyrosine kinase inhibitor Sensitive: C4 – Case Studies Tyrosine kinase inhibitor Sensitive : C4
EGFR A763_Y764insFQEA	Lung Adenocarcinoma	EGFR A763_Y764insFQEA	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D
EGFR A763_Y764insFQEA	Lung Adenocarcinoma	EGFR A763_Y764insFQEA	Lung Adenocarcinoma	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
EGFR A763_Y764insFQEA	Lung Adenocarcinoma	EGFR A763_Y764insFQEA	Lung Adenocarcinoma	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D